Clinical Research Directory

Inclusion Criteria: * 21-64 years old and healthy; * Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer; * Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel; * Have taken hemp or cannabis (in any form) before and tolerated it well; * Willing to abstain from consuming dietary supplements/botanical products and citrus juices for the duration of the study; * Willing to abstain from cannabis/marijuana, hemp, THC- and/or CBD-containing products for several weeks; * Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient day; * Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient day; * Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms), continuing for 1 week after completing the study; * Have the ability to and are willing to comply with the requirements of the study; * Geographically located within a 40-mile radius of Spokane and have the time to participate and; * Can read and speak English Exclusion Criteria: * Under the age of 21 or over the age of 64; * Any major illness; * Pregnant or nursing; * History of allergy or intolerance to cannabis or clopidogrel; * Taking concomitant medications, both prescription and non-prescription (including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel; * Never taken cannabis (in any form) before; * Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or the quality of the data; * Currently using or have recently used drugs or other illicit substances for recreational purposes; * Have used cannabis/marijuana, hemp, THC- and/or CBD-containing products within the last 4 weeks; * Have an out-of-range clinical laboratory value such that the study physician considers participation in the study a health risk, or; * Unable to read and speak English